# CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed

> **NCT05162976** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 33 (estimated)

## Conditions studied

- Recurrent Classic Hodgkin Lymphoma
- Refractory Classic Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** Nivolumab
- **DRUG:** Oral Azacitidine

## Key facts

- **NCT ID:** NCT05162976
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-01-03
- **Primary completion:** 2026-05-12
- **Final completion:** 2026-05-12
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2025-06-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05162976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05162976, "CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05162976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*